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Background: Interstitial cystitis/painful bladder syndrome (IC/PBS) is a chronic bladder disorder with bladder
epithelial thinning or ulceration, pain, urinary frequency and urgency. There is no reliably effective therapy for
IC/PBS, and no generally accepted animal model for the disorder in which potential therapies can be tested. Bladder
epithelial cells from IC/PBS patients make a small glycopeptide antiproliferative factor or "APF" that inhibits
proliferation, decreases tight junction protein expression, increases paracellular permeability, and induces changes in
gene expression of bladder epithelial cells in vitro that mimic abnormalities in IC/PBS patient biopsy specimens
in vivo. We therefore determined the ability of a synthetic APF derivative to inhibit bladder epithelial repair in mice.
Methods: The bladder epithelium of female CBA/J mice was stripped by transurethral infusion of 3% acetic acid, and
mice were subsequently treated daily with one of three intravesical treatments [synthetic as-APF, inactive
unglycosylated control peptide, or phosphate buffered saline carrier (PBS)] for 1–21 days. Fixed bladder sections
were either stained with haematoxylin and eosin for determination of epithelial area by image analysis, or incubated
with anti-uroplakin III (UPIII) or anti-zonula occludens type 1 (ZO-1) antibodies for immunofluorescence microscopy.
Epithelial measurement data were analyzed by a two-way analysis of variance (ANOVA); post hoc comparisons of
multiple groups were carried out using the Tukey-Kramer method.
Results: Bladder epithelial repair was significantly attenuated in as-APF-treated mice as compared to control mice
on days 3–21 (p< 0.05); the mean epithelial/total area over all measured days was also significantly lower in
as-APF-treated mice vs. mice in either control group by post hoc analysis (p< 0.0001 for both comparisons). UPIII
and ZO-1 expression was also decreased in as-APF-treated mice as compared to mice in either control group by day
7 (UPIII) or day 14 (ZO-1).
Conclusions: This model demonstrates in vivo effects of as-APF which abrogates bladder epithelial repair and
expression of UPIII and ZO-1 in CBA/J mice following transurethral acetic acid infusion. As bladder epithelial thinning,
decreased UPIII expression, and decreased ZO-1 expression are histopathologic features of IC/PBS patient biopsies,
this model may be useful for studying the pathophysiology of IC/PBS and the effect of potential therapies.
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Interstitial cystitis/painful bladder syndrome (IC/PBS) is
a chronic illness characterized by bladder epithelial thin-
ning or ulceration, pain, urinary frequency and urgency
[1-3]. The etiology of IC/PBS remains unknown, and no
treatment is reliably effective. Therefore, a greater
understanding of the pathogenesis of this debilitating
chronic painful bladder syndrome, along with the devel-
opment of animal models based on that pathogenesis,
may be necessary for the development of more effective
therapy(ies).
Epithelial abnormalities are indeed a cardinal finding in
bladder biopsies from IC patients, with predominant
histologic findings including denudation and tears in the
bladder epithelium (Hunner's ulcers or glomerulations)
and/or thinning of the bladder epithelium to 1–2 cell
layers thick [1-5]. Although tissue from patients with
Hunner's ulcers typically contains inflammatory cell infil-
trates in the epithelium (or lamina propria) that often
consists of T lymphocytes with or without mast cells
[1,3], little inflammation is usually seen in the epithelium
or submucosal interstitial tissue from the much larger
number of patients without ulcers [3], indicating that in-
flammation in tissue superficial to the detrusor muscle is
not a consistent finding in nonulcerative IC/PBS patients.
However, epithelial cell proliferation and gene expression
consistently appear to be abnormal in bladder tissue
from IC/PBS patients in vivo [6-12], and abnormalities in
cell proliferation and expression of most of the same
genes have also been demonstrated in isolated explanted
IC/PBS cells in vitro [13-20] with altered levels of specific
cell proteins [including increased E-cadherin, inducible
nitric oxide synthase (iNOS), plus P2X2 and P2X3 recep-
tors; but decreased uroplakin III (UPIII), zonula occlu-
dens type 1 (ZO-1), occludin, and vimentin]. Taken
together, these findings suggest an intrinsic bladder epi-
thelial cell defect with specifically altered epithelial cell
gene expression in IC/PBS patients.
To date, over 20 existing animal models of IC/PBS
have been described. With the exceptions of the natur-
ally occurring feline interstitial cystitis model and a
model involving spontaneous cystitis in estrogen recep-
tor beta-deficient mice, the other models generally in-
volve the induction of bladder inflammation and/or
epithelial damage via intravesical instillation of chemical
irritants, systemic instillation of self or foreign antigens
to induce an immune cell infiltrate in the bladder, or
systemic viral infection to induce bladder epithelial dam-
age [21-35]. While some of these models have been
shown to express altered bladder or immune cell expres-
sion of inflammatory cytokines, only a few have been
shown to exhibit abnormal expression of some of the
epithelial cell proteins found to be abnormally expressed
in IC/PBS patient biopsies (to date these have beenlimited to decreased ZO-1 in feline IC, decreased UPIII
in acrolein-induced and CYP-induced cystitis, and
increased iNOS in feline IC and CYP-induced cystitis);
therefore, the relationship of these models to the human
illness, or their utility for testing therapeutic or prevent-
ive agents for this syndrome, remains unknown.
In addition to the gene expression abnormalities noted
above, we discovered that the same IC/PBS cell explants
that express abnormal quantities of certain epithelial cell
proteins similar to those found in IC/PBS cell biopsies
also secrete a novel Frizzled 8-related glycopeptide “anti-
proliferative factor” (APF) [16,36,37] whose activity is
also found in urine of 94-97% of patients who fulfill the
symptomatic, exclusionary, and cystoscopic NIDDK cri-
teria for ulcerative or non-ulcerative IC and 93% of
patients who fulfill symptomatic and exclusionary cri-
teria alone [38-43]. This small sialoglycopeptide
(Neu5Acα2-3Galβ1-3GalNAcα-O-TVPAAVVVA) causes
abnormalities in normal bladder epithelial cells and blad-
der cancer cell lines that mimic changes seen in
explanted IC/PBS cells, including profoundly inhibited
cell proliferation [13,16,44], increased p53 and p21 ex-
pression [44,45], altered epithelial growth factor produc-
tion [16,46], and a specifically altered gene expression
pattern including increased E-cadherin with decreased
ZO-1, occludin, and vimentin [14,15]. APF may there-
fore play a role in the pathogenesis of IC/PBS by indu-
cing these abnormalities in vivo.
Prior patient studies indicate that the onset of IC/PBS
symptoms may be preceded by clinical evidence for a
urinary tract infection [47], and previous animal studies
indicate frequent shedding of the bladder epithelium as
part of a response to bacterial pathogens [48]. We there-
fore postulated that IC/PBS may occur following bladder
epithelial damage (as from bacterial cystitis or other
cause) in patients who have impaired bladder epithelial
repair because their epithelial cells secrete the APF
toxin. With this hypothesis in mind, we performed pilot
studies of a mouse model of IC/PBS based on inhibition
of bladder epithelial repair by synthetic as-APF, using
acetic acid to induce epithelial damage as previously
described for a rabbit model of cystitis as well as a rat
model of colitis [49,50], and determining bladder epithe-
lial area, UPIII and ZO-1 gene expression (all previously




Five to six week old female CBA/J mice (Harlan Labora-
tories, Frederick, MD) were anesthetized using 2-3% iso-
flurane in 100% oxygen via a precision vaporizer, their
bladders were infused transurethrally with 50 μl of 3%
acetic acid, and temporary reversible obstruction was
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lipsburg, NJ) to the external urethral meatus. The collo-
dion was removed 1 hour later with acetone, and the
mouse bladders were rinsed by transurethral infusion
with sterile phosphate buffered saline (PBS) (Quality
Biologicals, Inc., Gaithersburg, MD) and further infused
with one of three treatments (in 50 μl total volume):
250 mM synthetic as-APF (PolyPeptide Laboratories,
San Diego, CA), 250 mM inactive negative control pep-
tide (PolyPeptide Laboratories), or PBS carrier alone.
The bladders were then immediately obstructed for an
additional 3 hours with collodion, the collodion was
again removed, and the animals were returned to their
cages and allowed to void until the next day. Buprenor-
phine (0.05-0.1 mg/kg) was administered subcutaneously
to the mice every 8–12 hours for 48 hours to relieve any
discomfort resulting from acetic acid treatment. The
intravesical treatment infusion (with as-APF, peptide, or
PBS) was then repeated daily for 1–21 days until sacri-
fice by CO2 inhalation. NIH guidelines for the care and
use of laboratory animals for experimental procedures
were followed throughout the project, and this work was
approved by the Institutional Animal Care and Use
Committee of the University of Maryland, Baltimore.
Tissue fixation and staining
In anesthetized mice, bladder tissue was fixed in situ by
infusing 50 μL of 10% buffered neutral formalin (EMD,
Gibbstown, NJ) into the bladders with an infusion pump
(Harvard Apparatus, Millis, MA) over 30 seconds. Blad-
ders were then removed and fixed as a whole in 10% for-
malin overnight, after which they were embedded in
paraffin, cut into 6 μm sections, and either stained with
haematoxylin and eosin (H&E) or incubated with spe-








Figure 1 Inhibition of bladder epithelial repair in CBA/J/Hsd mice foll
mice treated with as-APF following bladder epithelial injury show inhibition
inactive control nonglycosylated peptide. A) 3 days of as-APF treatment; B
mice in each treatment group from one experiment; experiment performeFor immunofluorescence microscopy, sections were
deparaffinized, rehydrated, and incubated in 0.1% aque-
ous Saponin for 1 hour, after which they were treated
with Antigen Unmasking Solution (Vector Labs, Burlin-
game, CA) in a microwave oven for 15 minutes. Sections
were then incubated with mouse anti-bovine Uroplakin
III (clone 5 F161, US Biological, Swampscott Massachu-
setts) at 4 C overnight, followed by secondary antibody
goat anti-mouse IgG-FITC (Santa Cruz Biotechnology,
Santa Cruz, CA) at room temperature for 1 hour; or
FITC-conjugated mouse anti-ZO-1 (clone ZO-1-1A12,
Zymed Laboratories, Carlsbad, CA) at a 1:50 dilution in
1% Goat Serum (Vector Laboratories, Burlingame, CA).
Sections were finally rinsed with PBS, covered with Vec-
tashield mounting medium containing DAPI (Vector La-
boratories, Burlingame, CA), and examined using a Zeiss
Axio Observer Z1 motorized microscope with apotome
(Thornwood, NY).
Measurement of bladder tissue epithelial and total areas
Measurements of bladder cross sectional areas were
determined from 2X digital images using a Nikon
Eclipse TE300 Inverted Microscope with NIS-Elements
BR 3.00 Imaging Software with custom macros (Melville,
New York, USA). The two custom macros used were
created to measure the area of each cell layer in the
bladders [the epithelial layer (if present), the interstitial
layer, and the muscle layer]; one custom macro was used
for bladders that had an epithelial layer, while the other
was used in denuded bladders.
Statistical analysis
Epithelial area measurements were analyzed by analysis
of variance (ANOVA). Because the variance of these
measurements increased when the mean value increased,BS control
eptide control
s-APF-treated
owing treatment with as-APF. H&E stained bladder sections from
of epithelial regeneration as compared to mice treated with PBS or
) 14 days of as-APF treatment. Representative data shown for the 3
d five times. (200X final magnification).
BA
Figure 2 NIS-Elements BR 3.00 software image conversion for
quantification of total epithelial, subepithelial interstitial, and
muscularis layers of mouse bladder sections. A) Images of
H&E-stained mouse bladder sections (shown on left) were
generated at 20X using a Nikon Eclipse TE300 Inverted Microscope
and the area of specific tissue layers measured using NIS-Elements
BR 3.00 Imaging Software with custom macros (resulting image shown
on right). B) These images were then used to determine the ratio of
epithelial area to total bladder cross-sectional area for mice in each
treatment group for all time points using NIS-Elements BR 3.00 Imaging
Software. Data were combined from five experiments and analyzed
using two-way ANOVA; *p< .0001; **p< .01; ***p< .02; ****p< .04.
Treatment group: PBS □; inactive control peptide ■; as-APF ░:
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the variance, and performed two-way ANOVA (with
treatment group and day being the two factors) on the
transformed outcome variable. Post hoc comparisons of
multiple groups were carried out using the Tukey-
Kramer method. P< .05 was considered to indicate a
significant difference between groups.
Results
To determine whether the bladder epithelial thinning
found in PBS/IC bladder epithelial cells both in vivo
and/or in vitro might be caused by APF inhibition of
epithelial repair, we determined whether daily 3 hour
intravesical treatment with synthetic as-APF inhibited
normal bladder epithelial repair in 5–6 week old female
CBA/J/Hsd mice for 1, 2, 3, 4, 7, 14 or 21 days following
injury with 3% acetic acid. For each experiment, 3 mice
were treated with each of the 3 treatments (as-APF in
PBS, an equimolar concentration of inactive unglycosy-
lated APF peptide in PBS, or PBS vehicle alone). On days
1 and 2, there was no difference in the amount of epi-
thelial cells between treatment groups, with all but one
of the mice having no, or only one, layer of epithelial
cells in all 3 groups (the remaining one mouse in the
PBS control group had 3 layers of epithelial cells by day
2) (data not shown). However, as shown in Figure 1A, by
day 3 differences in the number of epithelial cell layers
were evident in the bladder of six week old female
CBA/J/Hsd mice treated daily with as-APF following
wounding with 3% acetic acid (0–1 layer of epithelial
cells) as compared to controls treated with either inactive
control unglycosylated APF peptide (1–4 layers of epithe-
lial cells) or PBS carrier alone (3–4 layers of epithelial
cells). In repeated experiments, all but one of the mice in
both control groups had 2–4 layers of bladder epithelial
cells by this day 3 time point, whereas most of the
as-APF-treated mice had only 1–2 layers of epithelial
cells, and the bladder wall remained denuded of epithe-
lium at the same time point for 7 of the 15 total animals
in this group, suggesting an inhibition of bladder epithe-
lial repair by as-APF.
Bladder epithelial repair continued during the subse-
quent days of the experiment, with the number of epi-
thelial cell layers generally increasing in all 3 treatment
groups (images shown for day 14 in Figure 1B, with
graphical results for all time points shown in Figure 2).
However, while the number of epithelial cell layers in
the as-APF-treated mice also increased from 0–1 on day
3 (Figure 1A) to 2–3 by day 14 (Figure 1B), these ani-
mals continued to have marked epithelial thinning as
compared to mice in either the inactive peptide (3–6 cell
layers) or PBS (4–6) control groups (Figure 1B), and the
epithelium in the as-APF-treated mice did not increase
further by day 21 (Figure 2).Because the apparent number of epithelial cell layers
can be influenced by bladder distension, digital images
were also obtained for measurement of the bladder epi-
thelium, subepithelial interstitium, and muscularis
(Figure 2A), and combined data from five total experi-
ments were analyzed by ANOVA (10–14 mice per
group on days 1,2,3,7 and 14; 3–5 mice per group on
days 4 and 21). As shown in Figure 2B, mice treated
with as-APF had decreased epithelial area throughout
the 21 days as compared to control mice, reaching sig-
nificance vs. one or both control groups on days 3–21





Figure 3 Inhibition of uroplakin III (UPIII) expression in CBA/J/Hsd mouse bladders following treatment with as-APF. Bladder sections
from mice treated with as-APF following bladder epithelial injury show decreased UPIII immunofluorescence staining as compared to mice
treated with PBS or inactive control nonglycosylated peptide. A) 7 days of as-APF treatment; B) 21 days of as-APF treatment. Representative data
shown for the 3 mice in each treatment group from one experiment; experiment performed three times. (200X final magnification).
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increasing variance). In comparison, there was no sig-
nificant difference in the mean ratio of epithelial/total
bladder cross sectional area between the two control
groups throughout the experiment. Post hoc analyses
indicated that the average of the transformed mean epi-
thelial/total area over all measured days is significantly
different between as-APF and PBS, as well as between
as-APF and peptide treatment groups (p< 0.0001 for
both comparisons), and confirmed that there was no
significant difference between PBS and peptide treat-
ment groups (p = 0.96).
In addition to bladder epithelial thinning, decreased
bladder epithelial expression of uroplakin III (UPIII) and
zonula occludens type 1 (ZO-1) has also been described
in bladder tissue from IC/PBS patients [6,7]. Therefore,
expression of both proteins in the regenerating bladder
epithelium was also determined in as-APF-treated vs.
control mice using immunofluorescence microscopy.
While little UPIII expression was evident in animals from
any of the treatment groups on days 1–4 (data not
shown), mice treated with either control compound
(inactive peptide or PBS) had increased UPIII expres-
sion in the superficial (more well-differentiated) blad-
der epithelial cells as compared to mice treated with
as-APF by day 7 (Figure 3A); negative controls stained
with an unrelated isotype control primary antibody or
with secondary antibody alone did not show evidence
for nonspecific background staining (data not shown).
This difference in UPIII expression continued with
mice in either control group having greatly increasedexpression as compared to as-APF-treated mice by day
21 (Figure 3B).
ZO-1 expression (evident as a small distinct enhanced
junctional area between cells in the terminally differen-
tiated luminal cell layer) was not clearly seen in any mice
in any treatment group up to and including day 7 of the
experiment (data not shown). While such areas of en-
hancement were definitely evident in the regenerating
epithelium from mice in all 3 treatment groups by day
14 (Figure 4), ZO-1 expression was also greater in the
control mice treated with inactive peptide or PBS as
compared to mice treated with as-APF. Negative con-
trols stained with an unrelated FITC-labeled antibody
did not show evidence for nonspecific background stain-
ing (data not shown).
Discussion
In this manuscript we present evidence that mice
treated with an active synthetic APF derivative [Galβ1-
3GalNAcα-O-TVAAVVVA] have decreased bladder
epithelial repair following intravesical acetic acid instilla-
tion. This finding mimics the bladder epithelial
thinning/ulceration found in biopsies from IC/PBS
patients [1-6] as well as the decreased proliferation seen
in both bladder epithelial cells explanted from IC/PBS
patients and as-APF-treated primary normal bladder
epithelial cells [13,36]. In addition, our data indicate
that as-APF treatment of these mice also resulted in
decreased expression of UPIII and ZO-1 in the regener-
ating epithelium, similar to abnormalities in expression




Figure 4 Inhibition of zonula occludens type 1 (ZO-1)
expression in CBA/J/Hsd mouse bladders following 14 days of
treatment with as-APF. Bladder sections from mice treated with
as-APF following bladder epithelial injury show decreased ZO-1
immunofluorescence staining (shown by small junctions between
cells indicated by arrows) as compared to mice treated with PBS or
inactive control nonglycosylated peptide. Representative data shown
for the 3 mice in each treatment group from one experiment;
experiment performed three times. (500X final magnification).
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epithelial cells from IC/PBS patients and as-APF-treated
primary normal bladder epithelial cells in vitro [15].
Finding a reliably effective treatment for IC/PBS has
been hampered for many years by the lack of a well-
understood inducible animal model with histologic/bio-
chemical features shared by the disease [22,35]. Many
putative animal models for IC/PBS have been developed
to date, but evidence for abnormal expression of the
same bladder epithelial proteins as documented in
human biopsy specimens is scant for these models. For
example, although the feline IC model and the protam-
ine sulfate rat model share evidence for decreased blad-
der epithelial tight junctions [51,52], only the feline IC
model has been documented to have decreased ZO-1
expression and increased epithelial permeability [51].
Like bladder tissue from IC/PBS patients, the feline IC
model also has been shown to have increased iNOS [23].
However, unlike patients with the human illness (who
exhibit increased P2X2 or P2X3 urothelial receptors)
cats with feline IC have decreased bladder epithelial
P2X1 receptor expression without abnormalities in
P2X2 or P2X3 expression [53]. In addition, because the
etiology of feline IC remains unknown it is not an indu-
cible model, and because of its sporadic and spontan-
eous nature cats with feline IC can be difficult for many
researchers to obtain.
Similarly, the relationship of the antigen-induced, vir-
ally-induced, chemical toxin-induced, or autoimmune
models of cystitis to the human disease are also not
clear, as there is no definite evidence for a similar patho-
genesis (with a defined antigen, virus, toxin, or autoanti-
gen) for the human disease [22]; therefore, although
these models are more readily available, their utility for
testing therapeutic or preventive agents for this syn-
drome also remains unknown. Abnormally expressed
bladder epithelial cell genes similar to those found in
bladder biopsies of IC/PBS patients have been limited to
UPIII [decreased in acrolein-induced cystitis [54] and
cyclophosphamide (CYP)-induced cystitis [55]], and
iNOS [increased in the CYP model] [56]. However, blad-
der epithelial cell UPIII expression rapidly normalizes
(within 24 hours) in the CYP-induced cystitis model,
and bladder hyperreflexia in these models can similarly
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of some of these changes in these models. Therefore,
additional studies are also required to compare the dur-
ability of abnormal bladder epithelial gene expression in
all of these models for us to understand the relative util-
ity of each model for studies of IC/PBS pathogenesis and
treatment.
The model described in this preliminary report has
certain advantages over the other animal models that
have been described to date. It is an inducible rodent
model, making it potentially more readily available than
the spontaneous feline model. This mouse model also
has changes in expression of two proteins similar to
changes found consistently in patients with IC/PBS –
UPIII and ZO-1. Unlike some protein expression abnor-
malities found in the other models to date, these
changes appear to be durable (sustainable) for up to
3 weeks. And whereas most of the other models are
induced by factors that are almost certainly not causative
in the pathogenesis of IC/PBS, this model is based on a
potential etiology of IC/PBS (APF) that was first discov-
ered in urine from patients with this illness, subse-
quently shown to be made by bladder epithelial cells in
these patients and to induce abnormal expression of at
least six epithelial proteins known to be abnormally
expressed in bladder tissue from IC/PBS patients
[14-16,36]. Because APF inhibits bladder epithelial cell
replication but does not by itself induce cell death
in vitro [13,16] we previously hypothesized that APF
may inhibit bladder epithelial repair following injury
caused by other inciting factors such as a urinary tract
infection [16,58]. However, the use of acetic acid to in-
duce such bladder epithelial injury prior to APF instilla-
tion in the current model is also by itself not related to
the pathogenesis of IC; future refinements to the model
may therefore include induction of epithelial shedding
by bacteria known to cause cystitis [48] prior to APF
instillation.
Disadvantages of this model, however, include its re-
quirement for daily intravesical instillations of active syn-
thetic APF (or its control peptide), making it relatively
labor-intensive and expensive for a rodent model. In
addition, some of the variability seen in this model regard-
ing the effects of APF on epithelial repair or gene expres-
sion may result from limited (only 3 hours daily) exposure
to the instilled APF. However, based on the preliminary
results from this model, development of a continuous
APF release model (via an implanted pump), or a trans-
genic mouse model that would express active APF either
constitutively or inducibly, appear to be warranted.
Conclusions
Bladder instillation of as-APF inhibits bladder epithelial
repair and expression of UPIII and ZO-1 in CBA/J micefollowing transurethral acetic acid infusion. Because
bladder epithelial thinning, decreased UPIII expression,
and decreased ZO-1 expression are consistently found in
IC/PBS patient bladder epithelial biopsies, this model
may be useful for studying the pathophysiology of this
illness, and the effect of potential therapies.
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